Owners, management and financials
CVR: 32280404
Previous names: MIRX THERAPEUTICS ApS, MIRX THERAPEUTICS A/S, MIRRX THERAPEUTICS A/S
DKK -409,444
Gross profit
Net result: DKK -843,419
QUERDENKER ApS (50-66,65%), Outlate Holding ApS (33,33-49,99%)
CVR · view owners
Hans Thorleif Møller
Board: Christina Møller Udesen (chair) and 3 members
CVR · view management
Active
Founded 1 July 2009
CVR · view overview
0 employees
CVR · 2018
Name registered: Ranger Biotechnologies A/S
CVR · 15/06/2018
View the full event history
Ranger Biotechnologies A/S is a Danish company of the type Aktieselskab based in Odense SØ, founded in 2009. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named MIRRX THERAPEUTICS A/S and MIRX THERAPEUTICS A/S. The management consists of Hans Thorleif Møller. The board consists of Christina Møller Udesen (chair), Hans Thorleif Møller, Kasper Tvede Larsen and Søren Tvede Larsen. The company is owned by QUERDENKER ApS and Outlate Holding ApS. The company has 0 employees (2018). In 2025, the company reported a gross profit of DKK -409,444 and a net result of DKK -843,419 compared with DKK -1,138,092 the year before. Equity in the 2025 report amounted to DKK 711,273.
Selskabets formål er at eje, skabe og forvalte immaterielle rettigheder samt hermed beslægtede aktiviteter.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | -409 t. | -843 t. | 756 t. | 711 t. | 1 | |
| 202401/01/2024 – 31/12/2024 | -224 t. | -1.1 mio. | 1.6 mio. | 1.6 mio. | 1 | |
| 202301/01/2023 – 31/12/2023 | 1.7 mio. | 1.4 mio. | 2.8 mio. | 2.7 mio. | 0 | |
| 202201/01/2022 – 31/12/2022 | 7.1 mio. | 372 t. | 2.7 mio. | 1.3 mio. | 11 | |
| 202101/01/2021 – 31/12/2021 | 5.7 mio. | 172 t. | 5.7 mio. | 889 t. | 9 | |
| 202001/01/2020 – 31/12/2020 | 2.4 mio. | 0 | 2.2 mio. | 717 t. | 3 | |
| 201901/01/2019 – 31/12/2019 | 591 t. | -12.7 mio. | 1.4 mio. | 717 t. | 2 | |
| 201801/01/2018 – 31/12/2018 | -832 t. | -975 t. | 14.4 mio. | 13.4 mio. | 1 | |
| 201701/01/2017 – 31/12/2017 | -1.3 mio. | -4.8 mio. | 15.2 mio. | 14.3 mio. | 1 | |
| 201601/01/2016 – 31/12/2016 | 2.1 mio. | 1.5 mio. | 14.3 mio. | 5.9 mio. | 1 | |
| 201501/01/2015 – 31/12/2015 | -733 t. | -633 t. | 9.7 mio. | 4.4 mio. | 1 | |
| 201401/01/2014 – 31/12/2014 | -1.2 mio. | -1.3 mio. | 7.6 mio. | 4.7 mio. | 1 | |
| 201301/01/2013 – 31/12/2013 | -699 t. | -1.1 mio. | 6.3 mio. | 6 mio. | 1 | |
| 201201/01/2012 – 31/12/2012 | -756 t. | -1.2 mio. | 6.2 mio. | 5.6 mio. | - |
Compared to 1.040 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningThe CVR number of Ranger Biotechnologies A/S is 32280404.
Ranger Biotechnologies A/S is owned by QUERDENKER ApS and Outlate Holding ApS.
The management of Ranger Biotechnologies A/S consists of Hans Thorleif Møller.
The board of Ranger Biotechnologies A/S consists of Christina Møller Udesen, Hans Thorleif Møller and Kasper Tvede Larsen, with Christina Møller Udesen as chair.
In 2025, Ranger Biotechnologies A/S reported a gross profit of DKK -409,444.
Ranger Biotechnologies A/S had 0 employees in 2018 according to the Danish CVR register.
Claim this page to add your logo and social links. Free to get started.
Ranger Biotechnologies A/S has published its annual report for 2025. Gross profit came to DKK -409,444, and the net result was DKK -843,419.
Address changed to C.F. Tietgens Boulevard 30A kl., 5220 Odense SØ (June 2, 2026).
Contact info changed: new phone: 53623170, new email: [email protected], new website: rangerbiotechnologies.com (June 2, 2026).
Ranger Biotechnologies A/S has published its annual report for 2024. Gross profit came to DKK -223,697, and the net result was DKK -1,138,092.
Ranger Biotechnologies A/S has published its annual report for 2023. Gross profit came to DKK 1,653,810, and the net result was DKK 1,431,531.
Ranger Biotechnologies A/S has published its annual report for 2022. Gross profit came to DKK 7,096,093, and the net result was DKK 371,913.
Ranger Biotechnologies A/S has published its annual report for 2021. Gross profit came to DKK 5,708,942, and the net result was DKK 171,975.
Ranger Biotechnologies A/S has published its annual report for 2020. Gross profit came to DKK 2,429,278, and the net result was DKK 0.
Ranger Biotechnologies A/S has published its annual report for 2019. Gross profit came to DKK 591,403, and the net result was DKK -12,653,117.
Ranger Biotechnologies A/S has published its annual report for 2018. Gross profit came to DKK -831,940, and the net result was DKK -975,295.
On June 15, 2018, the company changed its name from MIRRX THERAPEUTICS A/S to Ranger Biotechnologies A/S.
Ranger Biotechnologies A/S has published its annual report for 2017. Gross profit came to DKK -1,274,000, and the net result was DKK -4,850,000.
As of May 25, 2018, SØNDERJYLLANDS REVISION STATSAUTORISERET REVISIONSAKTIESELSKAB has been appointed auditor of Ranger Biotechnologies A/S.
As of May 25, 2018, EY Godkendt Revisionspartnerselskab has stepped down as auditor of Ranger Biotechnologies A/S.
As of May 25, 2018, Søren Tvede Larsen has joined the board of directors of Ranger Biotechnologies A/S.
As of May 25, 2018, Christina Møller Udesen has joined the board of directors of Ranger Biotechnologies A/S.
As of May 25, 2018, Kasper Tvede Larsen has joined the board of directors of Ranger Biotechnologies A/S.
As of May 25, 2018, Peter Buhl has left the board of directors of Ranger Biotechnologies A/S.
As of May 25, 2018, John Riis Mortensen has left the board of directors of Ranger Biotechnologies A/S.
As of May 25, 2018, Jarne Elleholm has left the board of directors of Ranger Biotechnologies A/S.
As of May 25, 2018, Søren Morgenthaler Echwald has left the board of directors of Ranger Biotechnologies A/S.
As of May 24, 2018, QUERDENKER ApS is registered as an owner of Ranger Biotechnologies A/S with an ownership share of 50%.
As of May 24, 2018, Outlate Holding ApS is registered as an owner of Ranger Biotechnologies A/S with an ownership share of 33%.
As of October 23, 2017, Peter Buhl has joined the board of directors of Ranger Biotechnologies A/S.
As of October 23, 2017, Jarne Elleholm has joined the board of directors of Ranger Biotechnologies A/S.
As of October 23, 2017, Finn Cilius Nielsen has left the board of directors of Ranger Biotechnologies A/S.
As of October 22, 2017, Peter Buhl has left the board of directors of Ranger Biotechnologies A/S.
Ranger Biotechnologies A/S has published its annual report for 2016. Gross profit came to DKK 2,138,000, and the net result was DKK 1,520,000.
Ranger Biotechnologies A/S has published its annual report for 2015. Gross profit came to DKK -733,000, and the net result was DKK -633,000.
As of May 19, 2015, Søren Morgenthaler Echwald has joined the board of directors of Ranger Biotechnologies A/S.
As of May 19, 2015, Palle Schelde Jensen has left the board of directors of Ranger Biotechnologies A/S.
Ranger Biotechnologies A/S has published its annual report for 2014. Gross profit came to DKK -1,167,000, and the net result was DKK -1,307,000.
Ranger Biotechnologies A/S has published its annual report for 2013. Gross profit came to DKK -699,000, and the net result was DKK -1,130,000.
Ranger Biotechnologies A/S has published its annual report for 2012. Gross profit came to DKK -755,567, and the net result was DKK -1,246,409.
As of May 31, 2013, Ole Bitsch-Jensen has left the board of directors of Ranger Biotechnologies A/S.
As of May 12, 2010, Ole Bitsch-Jensen has joined the board of directors of Ranger Biotechnologies A/S.
As of May 12, 2010, Peter Buhl has joined the board of directors of Ranger Biotechnologies A/S.
As of May 12, 2010, John Riis Mortensen has joined the board of directors of Ranger Biotechnologies A/S.
As of May 12, 2010, Hans Thorleif Møller is registered as adm. dir. of Ranger Biotechnologies A/S.
As of May 12, 2010, Palle Schelde Jensen has stepped down as adm. dir. of Ranger Biotechnologies A/S.
As of October 22, 2009, EY Godkendt Revisionspartnerselskab has been appointed auditor of Ranger Biotechnologies A/S.
As of October 22, 2009, SØNDERJYLLANDS REVISION STATSAUTORISERET REVISIONSAKTIESELSKAB has stepped down as auditor of Ranger Biotechnologies A/S.
On September 9, 2009, the company changed its name from MIRX THERAPEUTICS A/S to MIRRX THERAPEUTICS A/S.
As of September 7, 2009, Finn Cilius Nielsen has joined the board of directors of Ranger Biotechnologies A/S.
On July 3, 2009, the company changed its name from MIRX THERAPEUTICS ApS to MIRX THERAPEUTICS A/S.
As of July 1, 2009, SØNDERJYLLANDS REVISION STATSAUTORISERET REVISIONSAKTIESELSKAB has been appointed auditor of Ranger Biotechnologies A/S.
As of July 1, 2009, Palle Schelde Jensen has joined the board of directors of Ranger Biotechnologies A/S.
As of July 1, 2009, Hans Thorleif Møller has joined the board of directors of Ranger Biotechnologies A/S.
As of July 1, 2009, Palle Schelde Jensen is registered as adm. dir. of Ranger Biotechnologies A/S.
Ranger Biotechnologies A/S was founded on July 1, 2009.
Companies in the same industry and area
CVR 14689605
CVR 41218959
CVR 18073730
CVR 73109310
CVR 35671099
